Brolucizumab for Diabetic Macular Edema Treatment
Author Information
Author(s): Pastore Marco R., Milan Serena, Gouigoux Stefano, Colombo Olimpia, Rinaldi Silvia, Cirigliano Gabriella, Tognetto Daniele
Primary Institution: Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, Italy
Hypothesis
Can brolucizumab improve structural and functional outcomes in patients with diabetic macular edema?
Conclusion
Brolucizumab leads to anatomical and functional improvements in patients with diabetic macular edema.
Supporting Evidence
- BCVA significantly improved with a p-value of 0.003.
- CST showed significant reduction after each injection time point.
- 64.3% of patients had a dry macula at the last follow-up.
- A negative correlation between WHR and final CST was found.
Takeaway
This study shows that a new medicine called brolucizumab can help people with eye problems caused by diabetes see better and have healthier eyes.
Methodology
A retrospective observational study reviewing 28 eyes with diabetic macular edema switched to brolucizumab.
Limitations
The study had a small sample size and only included patients who did not respond to previous treatments.
Participant Demographics
{"sex_ratio":"16 male, 12 female","mean_age":69.31,"mean_diabetes_duration":21.2,"diabetes_type":"4 type 1, 24 type 2"}
Statistical Information
P-Value
p = 0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website